BNTX - BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript
2024-05-06 12:30:05 ET
BioNTech SE (BNTX)
Q1 2024 Earnings Conference Call
May 06, 2024 08:00 AM ET
Company Participants
Victoria Meissner - VP, Strategy & IR
Ugur Sahin - Co-Founder & CEO
Ozlem Tureci - Chief Medical Officer & Co-Founder
Jens Holstein - CFO
Ryan Richardson - Chief Strategy Officer
Conference Call Participants
Tazeen Ahmad - Bank of America
Daina Graybosch - Leerink Partners
Akash Tewari - Jefferies
Jessica Fye - JPMorgan
Brendan Smith - TD Cowen
Etzer Darout - BMO Capital
Terence Flynn - Morgan Stanley
William Maughan - Canaccord
Hartaj Singh - Oppenheimer
Ellie Merle - UBS
Simon Baker - Redburn Atlantic
Yifeng Liu - HSBC
Suzanne Van Voorthuizen - VLK
Presentation
Operator
Welcome to BioNTech’s First Quarter 2024 Earnings Call.
I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead.
Victoria Meissner
Thank you. Good morning, and good afternoon. Thank you for joining BioNTech's first quarter 2024 earnings call. As a reminder, the slides we will be using on this call and the corresponding press release we issued this morning can be found in the Investor Relations section of our website.
On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this call are subject to significant risks and uncertainties and speak only as of the date of this conference call. We undertake no obligation to update or revise any of these statements.
On Slide 3, you can find the agenda for today's call. Today, I am joined by the following members of BioNTech's management team. Ugur Sahin, Chief Executive Officer and Co-Founder; Ozlem Tureci, Chief Medical Officer and Co-Founder; Jens Holstein, Chief Financial Officer; and Ryan Richardson, Chief Strategy Officer.
With this, I would like to hand over to Ugur.
Ugur Sahin
Thank you, Victoria. A warm welcome to all those joining us today. We believe that we are entering a transformational period for BioNTech. We have founded BioNTech with the vision to discover and develop scientific great tools that harness the immune system to fight diseases and bring new medicines to patients.
In the years following our establishment, we developed various therapeutic platforms demonstrate the safety and clinical effectiveness of various drug candidates in early clinical trials. The period from now to 2030 is about progressing this candidate into late-stage development and registrational trials to become a multi-product company with the first product to be delivered by our late-stage oncology pipeline. We are continuing to execute this vision and our strategic priorities with its intense focus.
In the first quarter, we progressed our late-stage oncology pipeline on multiple fronts. We dosed the first patient in the pivotal Phase 3 clinical trial, evaluating our HER2 ADC BNT323 in HR positive HER2-low metastatic breast cancer....
BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript